October 06, 2021
Next week, the U.S. Food and Drug Administration (FDA) will evaluate the next steps for Moderna and Johnson & Johnson’s COVID-19 booster doses, as well as available research about mixing vaccine brands.
On October 14–15, the FDA’s advisory committee will discuss Moderna and Johnson & Johnson’s trial data and requests to authorize booster doses for their respective COVID-19 vaccines. Officials from both companies have said their vaccines provide strong protection against severe COVID-19, but that a third dose would improve protection against infection over time.
The meeting comes after the FDA and the Centers for Disease Control and Prevention (CDC) authorized a third dose of the Pfizer-BioNTech vaccine for certain individuals last month. The booster shot should be given at least six months after the completion of the initial two-dose series.
Here’s what you need to know about the FDA’s upcoming booster meetings:
The meetings on October 14 and October 15 will be available online.
This week, the Pennsylvania Department of Health issued its advisory for boosters of the Pfizer-BioNTech vaccine. Philadelphia released its recommendations last month.
HAP will continue to monitor COVID-19 booster developments and provide updates to members. For more information contact Robert Shipp III, PhD, BSN, RN, NEA-BC, vice president, population health and clinical affairs.
Tags: Public Health | COVID-19
Click on topic below for category-specific news articles.
Support a healthier Pennsylvania.